At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 56 enrolled
Drug / intervention
Bupivacaine Block +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Preemptive Sphenopalatine Ganglion Block on Anesthetic Requirements, Postoperative Pain and Functional Patient Outcomes After Functional Endoscopic Sinus Surgery
In Brief
A Phase 4 clinical trial evaluating Bupivacaine Block and Placebo for Pain, Postoperative. Completed, enrolled 56 participants across 1 site.
Detailed Summary
The aim of the study is to quantify postoperative pain after functional endoscopic sinus surgery (FESS) and investigate whether preemptive analgesia may positively impact intraoperative anesthetic management, decrease patient postoperative pain and discomfort, and improve patient functional outcomes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPain, Postoperative
CountriesUnited States
CollaboratorsHospira, now a wholly owned subsidiary of Pfizer
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2007
First PostedJun 2009
Primary CompletionMar 2010
Study CompletionAug 2010
TodayJul 2026
First PostedJun 25, 2009
Enrollment StartAug 1, 2007
Primary CompletionMar 1, 2010
Study CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 17.0 years ago
Interventions
Bupivacaine Blockdrug
Bupivacaine local anesthesia block prior to start of FESS procedure.
Placebodrug
placebo is identical in appearance in comparison to active drug.